乙型肝炎e抗原血清学清除后肝细胞癌和乙型肝炎表面抗原血清学清除的长期结局与预测评分
研究纳入723例乙型肝炎e抗原血清学清除患者,中位清除年龄36.0岁、中位随访18.3年,分析肝细胞癌和乙型肝炎表面抗原血清学清除的长期结局及其预测因素与评分。清除后20年肝细胞癌累积发生率7.9%、乙型肝炎表面抗原血清学清除累积发生率13.5%、总生存率91.5%。肝细胞癌预测评分和乙型肝炎表面抗原血清学清除预测评分在20年时的受试者工作特征曲线下面积分别为0.92和0.74。
要点
- 乙型肝炎e抗原血清学清除后20年肝细胞癌累积发生率为7.9%,乙型肝炎表面抗原血清学清除累积发生率为13.5%。
- 清除后丙氨酸氨基转移酶持续正常者仅3.5%,HBV DNA持续低于2logs IU/mL者仅3.0%。
- 男性、清除时年龄较大、丙氨酸氨基转移酶及较高HBV DNA水平与清除后肝细胞癌风险升高相关。
核心结论
- 男性、乙型肝炎e抗原血清学清除时年龄较大、丙氨酸氨基转移酶及较高水平HBV DNA与清除后肝细胞癌风险升高相关。
- 肝细胞癌预测评分和乙型肝炎表面抗原血清学清除预测评分可判断发生肝细胞癌和实现乙型肝炎表面抗原血清学清除的可能性。
研究设计与样本
- 研究纳入723例有记录的乙型肝炎e抗原血清学清除患者,每3至6个月随访一次,记录基线特征和纵向实验室结果。
- 肝细胞癌预测评分和乙型肝炎表面抗原血清学清除预测评分通过多因素Cox回归模型得出。
主要发现
- 中位乙型肝炎e抗原血清学清除年龄为36.0岁,中位随访18.3年。
- 清除后仅3.5%的患者丙氨酸氨基转移酶持续正常,仅3.0%的患者HBV DNA持续低于2logs IU/mL。
- 清除后丙氨酸氨基转移酶正常时间比例为100%、100%-90%、90%-50%、50%-10%、10%-0%和0%的患者,清除后20年肝细胞癌发生率分别为4.3%、2.2%、3.6%、3.9%、17.3%和37.2%(P < 0.001)。
- 清除后20年肝细胞癌累积发生率为7.9%,乙型肝炎表面抗原血清学清除累积发生率为13.5%,总生存率为91.5%。
- 肝细胞癌预测评分和乙型肝炎表面抗原血清学清除预测评分预测清除后20年肝细胞癌和乙型肝炎表面抗原血清学清除的受试者工作特征曲线下面积分别为0.92和0.74。
关键数值与推荐
- 肝细胞癌的显著因素包括清除时年龄、男性、肝硬化、低白蛋白血症、病毒载量和丙氨酸氨基转移酶。
- 乙型肝炎表面抗原血清学清除的显著因素包括清除时年龄、男性、病毒载量和抗病毒治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The significance of hepatitis B e-antigen (HBeAg) seroclearance (ESC) in the long term is not well defined. The current study aimed to determine the clinical outcomes, the factors and predictive scores for hepatocellular carcinoma (HCC), and hepatitis B surface antigen (HBsAg) seroclearance of a large cohort of patients undergoing ESC. Patients with documented ESC were followed up 3- to 6-monthly. Baseline characteristics and longitudinal laboratory results were recorded. Predictive scores for HCC (HCC-ESC) and HBsAg seroclearance (HBsAg-ESC) were derived from multivariate Cox regression models. A total of 723 patients underwent ESC with a median ESC age and follow-up of 36.0 and 18.3 years, respectively. Only 3.5% and 3.0% had persistently normal alanine aminotransferase (ALT) and HBV DNA <2logs IU/mL, respectively, after ESC. For patients with 100%, 100%-90%, 90%-50%, 50%-10%, 10%-0%, and 0% normal ALT after HBeAg seroclearance, the rate of HCC was 4.3%, 2.2%, 3.6%, 3.9%, 17.3%, and 37.2% at 20 years after ESC, respectively (P < 0.001). At 20 years after ESC, the cumulative incidence of HCC and HBsAg seroclearance was 7.9% and 13.5%, respectively, with an overall survival of 91.5%. ESC age, male sex, cirrhosis, hypoalbuminemia, viral load, and ALT were significant factors for HCC, whereas ESC age, male sex, viral load, and antiviral therapy were significant factors for HBsAg seroclearance. The area under receiver operating characteristics for HCC-ESC and HBsAg-ESC scores to predict HCC and HBsAg seroclearance at 20 years after ESC was 0.92 and 0.74, respectively. CONCLUSION: Male sex, older age at ESC, ALT, and higher level of HBV DNA were associated with higher rates of HCC after ESC. HCC-ESC and HBsAg-ESC predictive scores can determine the likelihood of developing HCC and achieving HBsAg seroclearance. (Hepatology 2018).
引用
- Fung J, Cheung KS, Wong DK, et al. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology. 2018. PMID: 29534307. doi:10.1002/hep.29874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。